Research programme: anticancer antibodies - Affitech/Roche

Drug Profile

Research programme: anticancer antibodies - Affitech/Roche

Alternative Names: AT 006; LC 06; LC 08

Latest Information Update: 10 Aug 2012

Price : $50

At a glance

  • Originator Affitech AS
  • Developer Affitech A/S; Roche
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Aug 2012 Research programme is still in active development
  • 16 Nov 2010 Preclinical pharmacodynamics data presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
  • 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top